Active	Status	Sponsor type	Region	Phase	Filter
1 Active 3 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
LY3200882 / Eli Lilly
NCT02937272: A Study of LY3200882 in Participants With Solid Tumors	Active, not recruiting	1	223	Europe, Canada, Japan, US, RoW	LY3200882, LY3300054, Gemcitabine, nab-Paclitaxel, Cisplatin, Intensity Modulated Radiotherapy	Eli Lilly and Company	Solid Tumor	02/20	08/25